Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

12:46pm IST
Change (% chg)

Rs35.30 (+1.46%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for REDY.BO


Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)


Beta: 0.15
Market Cap(Mil.): Rs432,694.09
Shares Outstanding(Mil.): 165.74
Dividend: 20.00
Yield (%): 0.77


  REDY.BO Industry Sector
P/E (TTM): -- 29.41 30.38
EPS (TTM): -- -- --
ROI: -- 13.85 13.36
ROE: -- 14.79 14.50

BRIEF-Dr.Reddy's Labs' audit of formulations Srikakulum plant Unit II completed with zero observations

* Says audit of formulations Srikakulum Plant unit II, Andhra Pradesh by US FDA, completed with zero observations. Source text - (http://bit.ly/2qnkt2M) Further company coverage:

25 May 2017

BRIEF-Dr.Reddy's Laboratories says USFDA approved launch of doxorubicin hydrochloride liposome injection in U.S.

* Announces USFDA approval for launch of doxorubicin hydrochloride liposome injection in U.S. Market Source text - (http://bit.ly/2qQ6RC6) Further company coverage:

17 May 2017

BRIEF-India's Dr.Reddy's Laboratories March-qtr consol profit rises about three-fold

* Consensus forecast for March quarter consol profit was 4.27 billion rupees

12 May 2017

BRIEF-Dr. Reddy's Labs launches Ezetimibe and Simvastatin tablets in U.S. market

* Says launch of Ezetimibe and Simvastatin tablets in U.S. market Source text for Eikon: Further company coverage:

27 Apr 2017

BRIEF-Fresenius sees no change in relationship of Merck KGaA's unit with partner Dr Reddy's

* Fresenius ceo sturm says we've had a good q1 but will not provide details

25 Apr 2017

BRIEF-Dr.Reddy's Laboratories announces launch of progesterone capsules in the U.S.

* Dr.Reddy's Laboratories - announces the launch ofprogesterone capsules in the U.S. market". Source text: (http://bit.ly/2pLTt0P) Further company coverage:

21 Apr 2017

BRIEF-Dr. Reddy's Labs, Integra Lifesciences sign deal to market Duragen products in India

* Co, Integra Lifesciences enter agreement to market, distribute Duragen plus and suturable duragen dural regeneration in India

27 Mar 2017

BRIEF-Cytosorbents Corp enters into a partnership with Dr. Reddy's laboratories

* Have entered into a partnership with Dr. Reddy's laboratories ltd for South African market

16 Mar 2017

BRIEF-Dr.Reddy's Labs gets form 483 with 3 observations from USFDA for audit of Miryalaguda plant

* Says the audit of API manufacturing plant at Miryalaguda, by the US FDA, has been completed on February 21, 2017

21 Feb 2017

BRIEF-Dr.Reddy's Labs says no claims against co for monetary damages

* Clarifies on news item "Dr. Reddy's announces US district court's opinion relating to patent infringement"

17 Feb 2017

More From Around the Web

Earnings vs. Estimates